Evidence map›Paper›PMID 31362019›Full record

ArticleJournal of molecular and cellular cardiology2019

Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome.

Hongwei Cheng, Chunyun Du, Yihong Zhang, Andrew F James, Christopher E Dempsey, Ana P Abdala, Jules C Hancox

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Breathing disturbances in Rett syndrome.Handbook of clinical neurology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Frontiers in cardiovascular medicine · 2021
    Article
  10. Arrhythmogenic late CaProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  11. An Update on the Structure of hERG.Frontiers in pharmacology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hongwei ChengSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Chunyun DuSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Yihong ZhangSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Andrew F JamesSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Christopher E DempseySchool of Biochemistry, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Ana P AbdalaSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Jules C HancoxSchool of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom. Electronic address: jules.hancox@bristol.ac.uk.
University of Bristol · GB

Funding

British Heart Foundation PG/15/106/31915British Heart Foundation PG/16/55/32277British Heart Foundation PG/17/89/33414
6 · The paper itself

Abstract

Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder associated with respiratory abnormalities and, in up to ~40% of patients, with prolongation of the cardiac QT

Indexed as

Action PotentialsAnimalsEther-A-Go-Go Potassium ChannelsGene Expression RegulationGuinea PigsHeart VentriclesHEK293 CellsHumansMaleMyocytes, CardiacOrganic ChemicalsRespiratory SystemRett SyndromeRisk FactorsTranscriptional Regulator ERGERG protein, humanEther-A-Go-Go Potassium ChannelsOrganic ChemicalssarizotanTranscriptional Regulator ERGhERGKCNH2Long QT syndromeRett SyndromeSarizotan

Identifiers

PMID31362019
PMCPMC6856717
OpenAlexW2965229752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.